1. Ticagrelor was non-inferior to DAPT for the incidence of major adverse cardiovascular and cerebrovascular events. 2. Ticagrelor monotherapy significantly ...
Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without ...
1. In patients with an established history of atherosclerotic cardiovascular disease (ASCVD) randomized to either take a daily high (325mg) ...
1. Dual antiplatelet therapy with ticagrelor and asprin led to a significantly lower risk of major adverse cardiovascular events over ...
Click here to read this study in JAMA Ophthalmology. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
1. Clinically relevant bleeding was significantly lower with ticagrelor monotherapy than in the ticagrelor plus aspirin group. 2. Major cardiovascular ...
1. Clinically relevant bleeding was significantly lower with ticagrelor monotherapy than in the ticagrelor plus aspirin group. 2. Major cardiovascular ...
Click here to read the study in JAMA. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
Click here to read this study in JAMA. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without ...
Click here to read this study in JAMA. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without ...
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
